Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir)

AIDS Research and Human Retroviruses

Volumn 15, Issue 7, 1999, Pages 619-624

  Lori, Franco ^a,f   Jessen, Heiko ^b   Lieberman, Judy ^c   Clerici, Mario ^d   Tinelli, Carmine ^e   Lisziewicz, Julianna ^a,f  

^a Research Institute for Genetic Human Therapy   (United States)

^b Jessen Praxis   (Germany)

^c CENTER FOR BLOOD RESEARCH   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f Research Institute for Genetic and Human Therapy (RIGHT)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA; INDINAVIR; T LYMPHOCYTE RECEPTOR;

ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIGENS, CD3; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYUREA; INDINAVIR; LYMPHOCYTE ACTIVATION; NUCLEIC ACID SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; VIREMIA;

EID: 0033136046     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310917     Document Type: Article

References (32)

1. Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS, and Gallo RC: Long-term cultures of HTLV-III-infected T cells: A model of cytopathology of T-cell depletion in AIDS. Science 1986;231:850-853.
2. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, and Chen IS: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 1990;61: 213-222.
3. Stevenson M, Stanwick TL, Dempsey MP, and Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO 1990;9:1551-1560.
4. Lori F, di Marzo Veronese F, de Vico AL, Lusso P, Reitz MS Jr, and Gallo RC: Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol 1992;66:5067-5074.
5. Phillips AN: Reduction of HIV concentration during acute infection: Independence from a specific immune response. Science 1996;271:497-499.
6. McLean AR, Emery VC, Webster A, and Griffiths PD: Population dynamics of HIV within an individual after treatment with zidovudine. AIDS 1991;5:485-489.
7. De Boer RJ, Boucher CA, and Perelson AS: Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998;12:1567-1570.
8. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JPA, Holohan MK, Leavitt R, Boone G, and Richman DD: Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998;339:1261-1268.
9. + T cell turnover. Science 1996;274:1543-1547.
10. Zinkernagel RM and Hengartner H: T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS. Immunol Today 1994;15:262-268.
11. Zinkernagel RM: Immunology taught by viruses. Science 1996; 271:173-178.
12. Donehower RC: An overview of the clinical experience with hydroxyurea. Semin. Oncol. 1992;19:11-19.
13. Gao WY, Cara A, Gallo RC, and Lori F: Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8928.
14. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, and Gallo RC: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-805.
15. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi-Sangasari F, and Vila J: Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retroviral 1995;10:36-40.
16. Vila J, Biron F, Nugier F, Vallet T, and Peyramond D: 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996;348:203-204.
17. Jessen H, Foli A, Lisziewicz J, and Lori F: Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA 1997;277: 1437-1438.
18. Lori F, Malykh AG, Foli A, Maserati R, De AA, Minoli L, Padrini D, Degli AA, Barchi E, Jessen H, Wainberg MA, Gallo RC, and Lisziewicz J: Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997;13: 1403-1409.
19. Montaner JS, Zala C, Conway B, Raboud J, Patenaude P, Rae S, O'Shaughnessy MV, and Schechter MT: A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175: 801-806.
20. Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher HC, Bernasconi E, Sudre P, Leduc D, Yerly S, Perrin LH, and Hirschel B: A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12:F71-F77.
21. Trimble LA and Lieberman J: Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood 1998;91:585-594.
22. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, and Shearer GM: Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989;84:1892-1899.
23. Shearer GM and Clerici M: Protective immunity against HIV infection. Has nature done the experiment for us? Immunol Today 1996;17:21-24.
24. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, and Leibowitch J: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
25. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, and Detels R: Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: Results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993; 6:904-912.
26. Mocroft A, Bofill M, Lipman M, Medina E, Borthwick N, Timms A, Batista L, Winter M, Sabin CA, Johnson M, Lee CA, Phillips A, and Janossy G: CD8+,CD38+ lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:158-162.
27. Borthwick NJ, et al.: Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28-T cells. AIDS 1994;8:431-441.
28. Lisziewicz J, Jessen H, Finzi D, Siliciano RE, and Lori F: HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998;352:199-200.
29. Vila J, Nugier F, Bargues G, Vallet T, Peyramond D, Hamedi-Sangsari F, and Seigneurin JM: Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 1997;350:635-636.
30. Martin LN, Murphey-Corb M, Mack P, Baskin GB, Pantaleo G, Vaccarezza M, Fox CH, and Fauci AS: Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys. J Infect Dis 1997;176:374-383.
31. Andrieu JM, Even P, Venet A, Tourani JM, Stern M, Lowenstein W, Audroin C, Eme D, Masson D, Sors H, et al.: Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol 1988;47:181-198.
32. Phillips A, Wainberg MA, Coates R, Klein M, Rachlis A, Read S, Shepherd F, Vellend H, Walmsley S, Halloran P, et al.: Cyclosporine-induced deterioration in patients with AIDS. Canadian Med Assoc J 1989;140:1456-1460.